Prognosis
Many Drugmakers Ignore Trump—and Raise Prices Anyway
- Celgene, Roche, Novo Nordisk boost prices on some top products
- Since 2016 election, Celgene blockbuster has risen 25 percent
This article is for subscribers only.
President Donald Trump succeeded in convincing Pfizer Inc. to hold off on price increases it had planned for this month.
But the pharmaceutical giant wasn’t the only drug company seeking to charge more for its products in recent days.